TED

Hong Kong International Optical Fair

Retrieved on: 
Mardi, octobre 31, 2023
Other Consumer, Communications, Consumer, Other Travel, Other Communications, Travel, Convention center, ANNA, Hong Kong Trade Development Council Trade Fairs, SUI, Fair, VOS, Gold, Shenzhen, LASH, HKTDC, Multimedia, TED, Lens, BIG, Smartglasses, Film industry, Wood, Mainland China

Organised by the Hong Kong Trade Development Council (HKTDC), the 31st edition of the Hong Kong International Optical Fair will be held from 8-10 Nov 2023 at the Hong Kong Convention and Exhibition Centre.

Key Points: 
  • Organised by the Hong Kong Trade Development Council (HKTDC), the 31st edition of the Hong Kong International Optical Fair will be held from 8-10 Nov 2023 at the Hong Kong Convention and Exhibition Centre.
  • View the full release here: https://www.businesswire.com/news/home/20231030817843/en/
    Organised by the Hong Kong Trade Development Council (HKTDC), the 31st edition of the Hong Kong International Optical Fair will be held from 8-10 Nov 2023 at the Hong Kong Convention and Exhibition Centre.
  • The fair includes group pavilions representing Italy, Japan, Korea, Taiwan, Visionaries of Style (VOS) as well as the Hong Kong Optical Manufacturers Association (HKOMA).
  • The Hong Kong Optical Manufacturers Association (HKOMA) will set up an eyewear design gallery under the theme of "Promoting Hong Kong's Outstanding Innovative Eyewear" to promote Hong Kong's creative eyewear designs and the 3D technology elements involved.

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Retrieved on: 
Lundi, octobre 30, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Citadel, LP, Sale, Security (finance), IND, Rare, Paradigm, Investment, Genzyme, LDL, Clinical trial, TED, Immunoglobulin G, Stifel, Autoimmunity, Safety, Therapy, Exchange, Patient, RTW, Colorado College, Pharmaceutical industry, Management, Neonatal Fc receptor, Boston College, Viridian

Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.

Key Points: 
  • Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.
  • He most recently served as President, Chief Financial and Operating Officer of Magenta Therapeutics.
  • Proceeds will be used to fund pipeline programs, including the FcRn portfolio, and for general corporate purposes and working capital.
  • Jefferies, Evercore ISI, and Stifel are acting as lead placement agents for the private placement financing.

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Retrieved on: 
Jeudi, octobre 26, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Graves' ophthalmopathy, Therapy, Patient, Pharmaceutical industry in Switzerland, TED, Pharmaceutical industry, Viridian

As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).

Key Points: 
  • As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).
  • “Developing a subcutaneous therapy is an essential part of our vision to offer the most comprehensive set of therapeutic options to the TED community.
  • “Thus, it’s critical that we continue to improve our therapy by packaging it in a delivery device that is as convenient and user-friendly as possible.
  • We engaged in a rigorous selection process and concluded that, based on its strong track record of drug-device combination approvals in multiple disease areas, Ypsomed is the ideal partner to supply such a device.

ThirdLine Analytics and Dr. Kelly Richmond Pope Join Forces to Combat Fraud in the Public Sector

Retrieved on: 
Jeudi, octobre 26, 2023
Professional Services, Data Management, Security, Technology, Data Analytics, Software, DePaul University, CPA, History, Prevalence, Fraud, Public sector, Forensic accounting, TED, Risk assessment, Diamond Jubilee Pageant, Senior advisor, Queen, Audit, Medical device

This collaboration represents a significant milestone of two industry experts in bolstering transparency, accountability, and fraud awareness within the public sector.

Key Points: 
  • This collaboration represents a significant milestone of two industry experts in bolstering transparency, accountability, and fraud awareness within the public sector.
  • In her role as Senior Advisor, Dr. Pope will partner with ThirdLine on thought leadership and industry research to bring awareness on the prevalence of government fraud and how to stop it.
  • About ThirdLine: ThirdLine is the public sector command center for auditing, financial monitoring, and business process improvement.
  • About Dr. Kelly Richmond Pope: Dr. Kelly Richmond Pope holds the position of Dr. Barry Jay Epstein Endowed Professor of Forensic Accounting at DePaul University in Chicago, IL.

.ART Registry Launches Inaugural Issue of .ART Odyssey Magazine, A Comprehensive Guide to the Future of Art

Retrieved on: 
Jeudi, octobre 26, 2023
Odyssey, Sale, FUTURE, Coffee, Non-fungible token, ART, Registry, TED, Art, Mental health, Video game, Kindle, Amazon

New Collectible Magazine Aims to Bridge the Gap Between Art, Technology, and Community, Offering Unique Insights, Interviews, and Practical Advice

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - October 26, 2023) - In line with its mission to nurture and support a dynamic global art community, .ART Registry proudly announces the launch of the .ART Odyssey Magazine.
  • The inaugural issue serves as a holistic guide to the evolving world of art, aiming to inspire, educate, and connect a diverse range of artists, creatives, and art-tech entrepreneurs.
  • "By venturing into topics ranging from digital art to mental health in the art space, we have created a resource that speaks to the challenges and opportunities in today's art landscape," said Ulvi Kasimov, Founder of .ART Registry.
  • Proceeds from the sale of the .ART Odyssey Magazine support The Art Therapy Initiative, reinforcing .ART Registry's commitment to making a positive impact by supporting and promoting widespread access to the healing powers of art.

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Retrieved on: 
Jeudi, octobre 19, 2023
LP, Biomarker, Guggenheim Partners, Literature, Graves' ophthalmopathy, Moyamoya disease, MD, TRML, IL-6, Paradigm, Inflammation, Research, Jefferies, SVB Securities, Spirited, Tourmaline Oil, Autoimmune disease, Eye, Investment, Patient, Death, Cooley LLP, Vaccine, Pharmaceutical industry, Talari Networks, Tourmaline, TED, ASCVD

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced the completion of its previously announced merger with Talaris Therapeutics, Inc. (“Talaris”). The combined company will operate under the name, Tourmaline Bio, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 20, 2023 under the ticker symbol “TRML”.

Key Points: 
  • The combined company will operate under the name, Tourmaline Bio, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 20, 2023 under the ticker symbol “TRML”.
  • Following the transactions, Tourmaline’s cash, cash equivalents and investments of approximately $218 million, before payment of final transaction-related expenses, is expected to fund operations through 2026.
  • Cooley LLP served as legal counsel to Tourmaline and Jefferies, Piper Sandler, Guggenheim Securities, and Truist Securities served as placement agents to Tourmaline in the private placement.
  • Leerink Partners served as exclusive financial advisor and Goodwin Procter LLP served as legal counsel to Talaris.

Alercell's Latest Intellectual Property In-License Bolsters Leukemia Diagnostic Test Advancements

Retrieved on: 
Mercredi, octobre 25, 2023
Leukemia, Patent, Therapy, Assistant, Oncology, Doctor of Philosophy, Columbia University Vagelos College of Physicians and Surgeons, Cell, TED, Physician, Chan, Columbia University, Classification, Patient, Diagnosis, Edward, Pharmaceutical industry, Surgeon, MD, Medicine

Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.

Key Points: 
  • Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.
  • Frederic Scheer, the Chief Executive Officer of Alercell, expressed immense enthusiasm regarding this patent license agreement, stating, "We are delighted to license this intellectual property from Columbia University.
  • At Alercell, our mantra is 'knowing before it is too late,' and licensing rights to the patent aligns seamlessly with our unwavering commitment."
  • Alercell's license agreement with Columbia University marks a significant stride for Alercell in the realm of cancer diagnostics, reinforcing the company's dedication to ushering in groundbreaking advancements in the field.

Jagdish Mahapatra Joins ColorTokens as Senior Vice President of Sales

Retrieved on: 
Mardi, octobre 24, 2023
Mohapatra, McAfee, Businessworld, SME, Entrepreneurship, India Inc., CrowdStrike, Managed services, Senior, Trust, Commercial, TED, Cisco, Culture, Management, Airline, Channel

SANTA CLARA, Calif., Oct. 24, 2023 /PRNewswire/ -- ColorTokens Inc., a leading Unified Zero Trust Platform provider, today announced the appointment of Jagdish Mahapatra as the company's Senior Vice President of Sales. In his new role, Mahapatra will lead ColorTokens sales team and provide strategic direction to business development, go-to-market, and alliance functions across the globe.

Key Points: 
  • SANTA CLARA, Calif., Oct. 24, 2023 /PRNewswire/ -- ColorTokens Inc. , a leading Unified Zero Trust Platform provider, today announced the appointment of Jagdish Mahapatra as the company's Senior Vice President of Sales.
  • In his new role, Mahapatra will lead ColorTokens sales team and provide strategic direction to business development, go-to-market, and alliance functions across the globe.
  • Mahapatra brings extensive knowledge to ColorTokens with more than 25 years of experience scaling businesses for companies such as Cisco, McAfee, and CrowdStrike.
  • Most recently, he served as Vice President for CrowdStrike's Asia region.

BOYS & GIRLS CLUBS OF METRO LOS ANGELES TO HONOR SUPER BOWL CHAMPION ANDREW WHITWORTH AND LOS ANGELES RAMS FOUNDATION AT 2023 GALA

Retrieved on: 
Jeudi, octobre 19, 2023
NFL, Los Angeles County Metropolitan Transportation Authority, Saturday Night Live, Emmy Awards, LASSO, Support, Boy, TED, Spectrum News, LOS, Vibiana, SNL, Video game, Film industry

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Philanthropists, business and entertainment community leaders, local dignitaries, and supporters will gather at Vibiana in Los Angeles for Boys & Girls Clubs of Metro Los Angeles' (BGCMLA) Stronger Together Gala on Saturday, October 21, 2023.

Key Points: 
  • Emmy Award-winning producer and journalist Tanya McRae will host the event, and Super Bowl LVI Champion and 2021 Walter Payton NFL Man of the Year Andrew Whitworth and the Los Angeles Rams Foundation will receive awards for their commitment and contributions that support justice and opportunity for youth.
  • Past honorees include Kiesha C. Nix of the LA Lakers Youth Foundation, Ed Magee of Fender Play Foundation, and Maggie Baird of Support + Feed.
  • Gala to be hosted by Emmy Award-winning producer and Spectrum News journalist Tanya McRae.
  • Super Bowl LVI Champion and 2021 Walter Payton NFL Man of the Year Andrew Whitworth and the Los Angeles Rams Foundation will receive awards for their commitment and contributions that support justice and opportunity for youth.

uni Brands Corporation Celebrates Courage Towards the Future at TEDWomen 2023

Retrieved on: 
Mercredi, octobre 18, 2023
Courage, Name, Woman, TED (conference), Uni, TED, Partnership, Creativity, Imagination, Nightclub

ATLANTA, Oct. 18, 2023 /PRNewswire/ -- From starting lines to dotted lines. uni Brands Corporation proudly partnered with TEDWomen 2023: "Two steps forward" in Atlanta, GA, from October 11th to 13th. The conference celebrated those taking bold strides into the future, working unapologetically to make big dreams become reality. The speaker casting was formed by people working on new models of equity and inclusion or blazing trails as pioneers, with names such as actress Glenn Close, writer Laurel Braitman, and many more.

Key Points: 
  • uni Brands Corporation proudly partnered with TEDWomen 2023: "Two steps forward" in Atlanta, GA, from October 11th to 13th.
  • The conference celebrated those taking bold strides into the future, working unapologetically to make big dreams become reality.
  • Attendees were encouraged to actively participate in making their mark on the mural by coloring it with vibrant POSCA markers from uni.
  • "Through symbolic paths that intertwine, these visuals reflect the strength and determination of women embracing uncertainty with courage," says Pennerman.